OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.53
+0.19 (+3.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.34
Open5.34
Bid5.56 x 2200
Ask5.52 x 800
Day's Range5.26 - 5.65
52 Week Range1.53 - 7.21
Volume1,219,467
Avg. Volume800,457
Market Cap302.79M
Beta (5Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

    NEW YORK, May 12, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire

    Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X syndromePreviously reported encouraging initial results.

  • GlobeNewswire

    Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

    OV101 met the study’s primary objective of safety and tolerabilityOV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with.

  • How Much Are Ovid Therapeutics Inc. (NASDAQ:OVID) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Ovid Therapeutics Inc. (NASDAQ:OVID) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • GlobeNewswire

    Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced initial data from its ongoing exploratory Phase 2 open-label ARCADE study of soticlestat (OV935/TAK935) in patients with CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q). CDD and Dup15q are two rare, highly refractory developmental and epileptic encephalopathies (DEE) that have no approved treatment options.

  • GlobeNewswire

    Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent progress and key clinical readouts anticipated in 2020. “We are entering a transformational period for Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. In anticipation of these important clinical readouts, during the fourth quarter of 2019 we raised approximately $56.0 million, providing us with sufficient capital to achieve all of these clinical data points.

  • GlobeNewswire

    Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

    NEW YORK, March 05, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire

    Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Alexander Kolevzon, M.D., a leader in child and adolescent psychiatry, to its Scientific Advisory Board (SAB).

  • GlobeNewswire

    Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

    NEW YORK, Feb. 25, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GuruFocus.com

    Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments

    Many other members of Big Pharma spent more on dividends and stock buybacks, a strategy some view as shortsighted Continue reading...

  • GuruFocus.com

    Pharma Company Buybacks: Do They Really Benefit Shareholders?

    Some argue cash spent on buybacks and dividends should be funneled into R&D; to develop novel therapies that create long-term value for investors Continue reading...

  • Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Invest In Growth?
    Simply Wall St.

    Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today outlined key clinical and business priorities for 2020.

  • Hedge Funds Have Never Been More Bullish On Ovid Therapeutics Inc. (OVID)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Ovid Therapeutics Inc. (OVID)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020
    TipRanks

    RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020

    The Cambridge Dictionary’s definition of an expert is a “person with a high level of knowledge or skill relating to a particular subject or activity.”Apply this to the investing world, and how do we see this in action? We pull out TipRanks’ Top Wall Street Firms and notice who sits at the top of the heap.Occupying the throne right now is renowned investment bank RBC Capital, which means that among the company’s employees there are seasoned pros with a proven track record for success. Utilizing the TipRanks Stock Screener tool, we’ve found three stocks receiving Strong Buy ratings from most analysts in general, and endorsed by RBC in particular. Let’s take a closer look: Ovid Therapeutics (OVID)Ovid Therapeutics shares are on a tear. The stock price of this neurological medicines firm has raced ahead 66% this year, leaving the Nasdaq Biotechnology ETF (IBB) in its dust. But would you believe it has even further to run? Would you believe it could go up another 200%? RBC analyst Brian Abrahams does. In his latest research note, Abrahams reiterated an Outperform rating on OVID, along with a price target of $12.00 (To watch Abraham’s track record, click here)The drug maker has several therapies in the pipeline. Leading programs in development right now are OV101, which focuses on a potential treatment for Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders caused by genetic mutations, and OV935, a program focused on developing potential therapies for people living with rare epilepsies.Top-line data from a Phase 3 NEPTUNE trial of OV101 in Angelman's Syndrome should be released in mid-2020, and Abrahams thinks there is a very reasonable chance of success. While acknowledging some risk given disease heterogeneity, unclear dose dependence, and inconsistent subdomain effects in ph.II, the 5-star analyst noted, “We believe clinical and preclinical data for the company's lead candidate OV101, an extrasynaptic GABAA receptor agonist, are in totality supportive of the drug's activity in Angelman Syndrome, and believe the stock price currently underappreciates the likelihood the drug succeeds in improving clinical symptoms of the disease in ph.III. Given the high unmet need in this population, we believe FDA will be permissive -- highlighted by the Agency's endorsement of the pivotal trial design -- and if approved, should enable good uptake and pricing power.”Other analysts are even more optimistic. Indeed, the average price target on Wall Street is $13.50 -- implying nearly 240% upside. And over the last three months, no one on the Street has assigned Ovid shares anything less than a "buy" rating. (See Ovid stock analysis on TipRanks)Anaplan (PLAN)This year has seen a number of car crash IPO’s, as several over valued startups got on the receiving end of a harsh reality check following public listings. One to avoid such a fate, is cloud computing ‘connected planning’ platform, Anaplan.The company’s name derives from the combination of analysis and planning, which makes sense to us, as it makes software that connects people in a shared environment to business data in order to make better-informed plans and decisions.Anaplan impressed Wall Street with its latest F3Q20 earnings report. The company handily beat expectations on several key metrics, including top-line, billings, and margins. Additionally, this led to management significantly boosting its FY20 guidance.RBC’s Alex Zukin believes that a ‘large addressable market’ can serve as a catalyst for Anaplan’s growth, noting, “Anaplan indicates that the Planning market is a $21B+ opportunity (based on IDC forecasts). We believe customers are paying legacy vendors billions of dollars today and there is potential for spend significantly above that if greenfield, excel-based business processes meaningfully start to convert to Planning vendors.”Anaplan’s growth potential has Zukin reiterating his Outperform rating, along with a price target of $70. PLAN is currently trading at $52.56, indicating gains of 33% might be in the cards should Zukin’s target materialize. (To watch Zukin’s track record, click here)What’s the Street’s plan for PLAN, then? The consensus is that the connected planning innovator is a Strong Buy, a rating achieved as a result of 9 "buy" and 3 "hold" ratings issued in the past 3 months. The average stock-price forecast of $63.33 implies upside potential of 20% from current levels. (See PLAN stock analysis on TipRanks)Analog Devices (ADI)Last and least, we come to semiconductor maker Analog Devices, which scored an "outperform" rating (i.e. "buy") from 5-star RBC analyst Mitch Steves.ADI stock is up nearly 38% in 2019 compared to the S&P 500, which has returned 24%. That’s impressive, but the big question for investors is whether the company (and its stock) can maintain the momentum. Steves suggests that if everything goes as planned, ADI will be a $136 stock in the next 12 months, implying about 18% return. (To watch Steves’ track record, click here)The company’s recent FQ4 numbers were mildly below Street expectations. Revenues of $1.44 billion slightly missed the Street’s estimate of $1.45 billion, while EPS of $1.19 came below the $1.22 estimate. FQ1 guidance also missed the Street’s targets.Steves commented, “We continue to believe that sentiment is still quite negative on the stock and remain positive as operating margin expansion should begin in Q2 and beyond [...] We remain positive on ADI and its suggestion of a recovery in Q2 is in line with our Analog view as well.” The analyst further added, “We are seeing positive trends within ADI’s communications business, as the company manages to sustain share gain and capture 5G opportunities. Being exposed to 5G radio content represents significant differentiation relative to the analog group, in our view.”The RBC expert is not alone in his take on ADI, as 11 Buys and 3 Holds from the analysts tracked by TipRanks over the last 3 months result in a Strong Buy consensus rating. The average price target stands at $125.57. (See ADI stock analysis on TipRanks)

  • GlobeNewswire

    Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

    NEW YORK, Nov. 26, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire

    Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Jason Tardio as Chief Commercial Officer. Mr. Tardio brings to Ovid broad global commercial leadership experience within the pharmaceutical and biotechnology industries, having most recently served as Vice President and Head of the Multiple Sclerosis franchise at Novartis. “2020 will be a year of transformation for Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

  • GlobeNewswire

    Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

    Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency.

  • GlobeNewswire

    Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced two senior leadership changes to further build the company’s capabilities as it approaches topline results from the pivotal Phase 3 NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. Ovid’s Chief Medical Officer and Head of Research and Development, Amit Rakhit, M.D., MBA, has been promoted to President, in which role he will oversee several functions including commercial, research and development, regulatory, and manufacturing.

  • Will Ovid Therapeutics Continue to Surge Higher?
    Zacks

    Will Ovid Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Ovid Therapeutics.

  • Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares
    Simply Wall St.

    Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares

    Investors who take an interest in Ovid Therapeutics Inc. (NASDAQ:OVID) should definitely note that the Chairman & CEO...

  • GlobeNewswire

    Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of two concurrent but separate underwritten public offerings (together, the “Offerings”) of (i) 9,000,000 shares of its common stock and (ii) 4,000 shares of its non-voting Series A Convertible Preferred Stock (the “Series A preferred stock”). The public offering price of each share of common stock is $2.50 and the public offering price of each share of Series A preferred stock is $2,500 (each share of Series A preferred stock is convertible into 1,000 shares of common stock).

  • Benzinga

    The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) ...

  • GlobeNewswire

    Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock (the “Series A preferred stock”) in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A preferred stock offering (together, the “Offerings”) are contingent upon the consummation of the other. Cowen and William Blair are acting as joint book-running managers for the Offerings.

  • GlobeNewswire

    Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Ovid Therapeutics Inc. (OVID) today announced positive initial data from the ENDYMION trial, a Phase 2 open-label extension study of soticlestat (OV935/TAK935) in patients with rare developmental and epileptic encephalopathies (DEE). Soticlestat is a potent, highly-selective first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) being investigated as a novel approach to treating adults and children with rare epilepsies in collaboration with Takeda Pharmaceutical Company Limited.